CURE^® Expert Connections

Shared insight on the current treatment landscape for myeloproliferative neoplasms (MPNs), including novel therapies for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).

Thomas Hutson, DO, PharmD discusses the role of tivozanib in the treatment landscape for patients with renal cell carcinoma.

An expert oncologist and a patient advocate work together to discuss the importance of EGFR exon20 treatment in metastatic non-small cell lung cancer.

Jessica Donington, MD, MSCR, and Martin Dietrich, MD, PhD, have a thorough discussion on the management of early non-small cell lung cancer, including treatment options and the role of adjuvant therapy.

Expert oncologist Julie Fisher, MD, is joined by her patient Jocelyn Mueller, who shares her personal journey with HER2-positive breast cancer.

A discussion pertaining to the significance of biomarker testing and precision medicine in non–small cell lung cancer.

Expert hematologist/oncologist Kenneth Shain, MD, PhD, is joined by Marcella Worrell, a survivor of multiple myeloma, who shares her story of diagnosis, treatment, and support.

Thomas E. Hutson, DO, PharmD, shares insight on the role of combination therapy and recent advances for the management of renal cell carcinoma.

Anna C. Pavlick, DO, discusses locally advanced basal cell carcinoma and various treatment options for patients and caregivers.

A survivor of triple-negative breast cancer, Latasha Jordan, and an expert breast oncologist, Aditya Bardia, MD, MPH, provide key insights into the patient experience in triple-negative breast cancer and highlight the role of clinical trials in the current treatment landscape.

Cristina Gasparetto, MD, is joined by her patient, Donna, as they discuss her particular experience with diagnosis and treatment of multiple myeloma.

An expert in thoracic oncology, Adam J. Schoenfeld, MD, provides key insight into the use of cell therapy in non-small cell lung cancer after first-line treatment and highlights the potential for tumor-infiltrating lymphocyte (TIL) therapy depending on results from ongoing clinical trials.

Insight regarding the role of comprehensive biomarker testing non-small cell lung cancer to help individualize therapy.

This series follows one patient’s journey with multiple myeloma through diagnosis and treatment information, provided by Elie Fahed, MD.

Sara A. Hurvitz, MD, discusses information about HER2+ metastatic breast cancer with one of her patients, Caitlin Flanagan, as she shares her personal journey with breast cancer.